Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$19.62 +2.9%	$20.93	$18.64 ▼ $30.63	$12.98B	0.98	920,961 shs	1.32 million shs
ITCI Intra-Cellular Therapies	$131.69 0.0%	$128.89	$64.09 ▼ $131.79	$14.00B	0.69	1.34 million shs	1.02 million shs
SMMT Summit Therapeutics	$19.89 -1.7%	$20.44	$2.10 ▼ $33.89	$14.67B	-1.04	3.39 million shs	2.71 million shs
ZLAB Zai Lab	$33.91 -4.2%	$31.32	$13.48 ▼ $39.61	$3.72B	1.08	748,365 shs	736,475 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+2.94%	-3.11%	-12.80%	-4.66%	-36.36%
ITCI Intra-Cellular Therapies	-0.01%	+0.12%	+2.43%	+53.13%	+95.59%
SMMT Summit Therapeutics	-1.73%	-1.09%	+5.57%	+3.16%	+431.82%
ZLAB Zai Lab	-4.21%	-10.79%	+2.91%	+24.58%	+112.60%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	4.068 of 5 stars	4.4	3.0	0.0	2.5	0.0	3.1
ITCI Intra-Cellular Therapies	3.6489 of 5 stars	2.2	3.0	4.5	3.0	1.7	0.6
SMMT Summit Therapeutics	2.6953 of 5 stars	4.5	2.0	0.0	2.1	1.7	0.0
ZLAB Zai Lab	2.5933 of 5 stars	3.5	1.0	0.0	3.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.77	Moderate Buy	$41.33	110.67% Upside
ITCI Intra-Cellular Therapies	2.47	Hold	$106.08	-19.45% Downside
SMMT Summit Therapeutics	3.00	Buy	$35.44	78.20% Upside
ZLAB Zai Lab	3.00	Buy	$47.37	39.68% Upside

Current Analyst Ratings Breakdown

Latest ZLAB, SMMT, ITCI, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2025	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$23.00 ➝ $35.00
3/21/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
3/13/2025	ZLAB Zai Lab	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$44.00 ➝ $51.00
3/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/11/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
3/11/2025	GMAB Genmab A/S	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/7/2025	ZLAB Zai Lab	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$55.00
3/4/2025	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/3/2025	ZLAB Zai Lab	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$29.00 ➝ $36.10
2/28/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
2/25/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00

(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$21.53B	0.60	$1.33 per share	14.80	$8.04 per share	2.44
ITCI Intra-Cellular Therapies	$680.50M	20.58	N/A	N/A	$6.15 per share	21.41
SMMT Summit Therapeutics	$700K	20,960.65	N/A	N/A	$0.11 per share	180.82
ZLAB Zai Lab	$398.99M	9.32	N/A	N/A	$8.05 per share	4.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.74	11.28	11.02	2.65	36.30%	16.78%	13.79%	5/1/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	693.11	N/A	-14.07%	-9.93%	-8.38%	5/6/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.31	N/A	N/A	N/A	N/A	-85.42%	-52.66%	4/29/2025 (Estimated)
ZLAB Zai Lab	-$334.62M	-$2.59	N/A	N/A	N/A	-76.14%	-36.97%	-27.10%	5/6/2025 (Estimated)

Latest ZLAB, SMMT, ITCI, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/27/2025	Q4 2024	ZLAB Zai Lab	-$0.61	-$0.80	-$0.19	-$0.80	$110.15 million	$109.07 million
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.25	5.24
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	8.31	8.31
ZLAB Zai Lab	N/A	3.01	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	88.30%
ZLAB Zai Lab	13.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,204	661.77 million	651.58 million	Optionable
ITCI Intra-Cellular Therapies	560	106.33 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	737.68 million	86.28 million	Optionable
ZLAB Zai Lab	1,950	109.63 million	94.24 million	Optionable

ZLAB, SMMT, ITCI, and GMAB Headlines

Recent News About These Companies

Fox Run Management L.L.C. Purchases New Holdings in Zai Lab Limited (NASDAQ:ZLAB)

March 27 at 4:31 AM | marketbeat.com

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

March 26 at 9:04 AM | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Time to Sell?

March 22, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) Shares Purchased by DCF Advisers LLC

March 22, 2025 | marketbeat.com

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

March 21, 2025 | seekingalpha.com

Zai Lab Limited (NASDAQ:ZLAB) Insider Rafael Amado Sells 3,000 Shares

March 20, 2025 | marketbeat.com

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

March 20, 2025 | seekingalpha.com

Rafael Amado Sells 3,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

March 20, 2025 | insidertrades.com

Privium Fund Management B.V. Has $4.85 Million Position in Zai Lab Limited (NASDAQ:ZLAB)

March 20, 2025 | marketbeat.com

Zurcher Kantonalbank Zurich Cantonalbank Invests $1.67 Million in Zai Lab Limited (NASDAQ:ZLAB)

March 18, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sets New 1-Year High After Analyst Upgrade

March 15, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $51.00 at JPMorgan Chase & Co.

March 14, 2025 | marketbeat.com

Is Zai Lab Limited (ZLAB) the Best Performing Growth Stock in 2025?

March 14, 2025 | insidermonkey.com

Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Zai Lab Limited (NASDAQ:ZLAB)

March 14, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Perspective Therapeutics (CATX) and Edesa Biotech (EDSA)

March 13, 2025 | markets.businessinsider.com

Zai Lab price target raised to $51 from $44 at JPMorgan

March 13, 2025 | markets.businessinsider.com

Zai Lab Limited Announces Equity Incentive Grants

March 13, 2025 | tipranks.com

Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer

March 12, 2025 | markets.businessinsider.com

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

March 12, 2025 | businesswire.com

Zai Lab (ZLAB) Initiated with a Buy at Scotiabank

March 10, 2025 | markets.businessinsider.com

Scotiabank Initiates Coverage of Zai Lab Limited - Depositary Receipt () (ZLAB) with Sector Outperform Recommendation

March 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB, SMMT, ITCI, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$19.62 +0.56 (+2.94%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$19.63 +0.01 (+0.06%)

As of 03/26/2025 05:00 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

$131.69 -0.01 (-0.01%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$131.68 -0.01 (-0.01%)

As of 03/26/2025 07:02 PM Eastern

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$19.89 -0.35 (-1.73%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$19.95 +0.06 (+0.33%)

As of 03/26/2025 07:49 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Zai Lab NASDAQ:ZLAB

$33.91 -1.49 (-4.21%)

Closing price 03/26/2025 04:00 PM Eastern

Extended Trading

$34.18 +0.28 (+0.81%)

As of 03/26/2025 07:24 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time